Arnatar Therapeutics Receives China NMPA Clearance to Initiate First-in-Human Study of ART5, a First-in-Class Up-Regulating ASO Designed to Restore Polycystin-1 for the ...

ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers ...
Oil

Canadian Natural Resources plans 12% year-over-year production increase at midpoint

Canadian Natural Resources Ltd., Calgary, expects its 2025 operating capital budget of $6 billion (Can.) to deliver annual average production of 1.510-1.555 MMboe/d, a 12% increase over 2024 levels at ...